A recent phase II trial with the HIF-2 alpha inhibitor belzutifan (MK-6482) demonstrated promising efficacy and tolerability in patients with VHL-mutated cancers, including RCC, and the drug has recently been approved by the FDA for this indication [43,44]. The gene discussed is VHL; the disease is renal cell carcinoma.